OAC Risk Similar With SGLT2i and DPP4i in T2DM Tags DPP-4 inhibitors SGLT-2 Inhibitor Read more about OAC Risk Similar With SGLT2i and DPP4i in T2DM
Canagliflozin Reduces Myocardial Fibrosis on CMR in T2DM Tags MRI Chest Myocardial infarction hBA1c SGLT-2 Inhibitor Read more about Canagliflozin Reduces Myocardial Fibrosis on CMR in T2DM
GLP-1RAs Rarely Used as Early Therapy in T2DM Tags GLP-1 agonists SGLT-2 Inhibitor Read more about GLP-1RAs Rarely Used as Early Therapy in T2DM
Salt-Related BP Changes Differ With SGLT2 Therapy Tags SGLT-2 Inhibitor Read more about Salt-Related BP Changes Differ With SGLT2 Therapy
AF Patients on OAC Show Higher Erythrocytosis With SGLT2 Inhibitors Tags SGLT-2 Inhibitor Read more about AF Patients on OAC Show Higher Erythrocytosis With SGLT2 Inhibitors
Liraglutide Shows No Significant CIMT Change in Adults With T1DM Tags Peripheral vascular disease Read more about Liraglutide Shows No Significant CIMT Change in Adults With T1DM
GLP-1 RAs Show No Significant Limb Outcome Differences in PAD Tags Diabetic Neuropathy Diabetic Neuropathy Read more about GLP-1 RAs Show No Significant Limb Outcome Differences in PAD
Real-World Tirzepatide Outcomes in Japanese Patients With T2DM Tags Urban living Hyperglycemia hyperosmolar state Lipohypertrophy Read more about Real-World Tirzepatide Outcomes in Japanese Patients With T2DM
Global Survey Reports Perceived Disparities in Diabetes Drug Access Tags Rapid acting short acting Long acting α-Glucosidase inhibitors SGLT-2 Inhibitor Read more about Global Survey Reports Perceived Disparities in Diabetes Drug Access
Meta-Analysis of 42 RCTs Compares Safety of SGLT2 Inhibitors and DPP-4 Inhibitors in Type 2 Diabetes Tags SGLT-2 Inhibitor Read more about Meta-Analysis of 42 RCTs Compares Safety of SGLT2 Inhibitors and DPP-4 Inhibitors in Type 2 Diabetes